TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Down 37.2% in March

Posted by Casey Walker on Mar 29th, 2025

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 339,800 shares, a drop of 37.2% from the February 28th total of 540,900 shares. Currently, 54.3% of the company’s stock are short sold. Based on an average daily volume of 6,040,000 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of TransCode Therapeutics in a research note on Thursday, March 13th.

View Our Latest Analysis on RNAZ

TransCode Therapeutics Trading Down 5.8 %

Shares of NASDAQ RNAZ traded down $0.03 during trading hours on Friday, hitting $0.49. The company had a trading volume of 22,887,058 shares, compared to its average volume of 1,742,585. TransCode Therapeutics has a 1-year low of $0.49 and a 1-year high of $66.33. The firm’s 50 day moving average is $5.01 and its 200-day moving average is $217.77.

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.